ixekizumab (Rx)

Brand and Other Names:Taltz
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

prefilled autoinjector, single-dose

  • 80mg/mL

prefilled syringe, single-dose

  • 80mg/mL

Psoriasis

Indicated for moderate-to-severe plaque psoriasis

Week 0: 160 mg SC (two 80-mg injections), THEN

Weeks 2, 4, 6, 8, 10, and 12: 80 mg SC q2Weeks, THEN

Week 16 and thereafter: 80 mg SC q4Weeks

Psoriatic Arthritis

Indicated for active psoriatic arthritis

May be administered alone or in combination with a conventional DMARD (eg, methotrexate)

160 mg SC (ie, as two 80-mg injections) at Week 0, THEN 80 mg SC q4Weeks

For patients with coexisting moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis

Ankylosing Spondylitis

Indicated for active ankylosing spondylitis

160 mg SC (ie, as two 80-mg injections) at Week 0, THEN 80 mg SC q4Weeks

May be administered with conventional (nonbiologic) DMARDs (eg, sulfasalazine), corticosteroids, NSAIDs, and/or analgesics

Non-radiographic Axial Spondyloarthritis

Indicated for active non-radiographic axial spondyloarthritis with objective signs of inflammation

80 mg SC q4Weeks

Dosage Modifications

Hepatic or renal impairment

  • No formal trial of the effect of hepatic or renal impairment on the pharmacokinetics of ixekizumab was conducted

Dosing Considerations

Evaluate for tuberculosis (TB) before initiating treatment

Plaque Psoriasis

Indicated for moderate-to-severe plaque psoriasis in children and adolescents aged ≥6 years who are candidates for systemic therapy or phototherapy

<6 years: Safety and efficacy not established

≥6 years

  • <25 kg: 40 mg SC at Week 0, THEN 20 mg SC q4Weeks thereafter
  • 25 to 50 kg: 80 mg SC at Week 0, THEN 40 mg SC q4Weeks thereafter
  • >50 kg: 160 mg SC (ie, as two 80-mg injections) at Week 0, THEN 80 mg SC q4Weeks

Dosage Modifications

Hepatic or renal impairment

  • No formal trial of the effect of hepatic or renal impairment on the pharmacokinetics of ixekizumab was conducted

Dosing Considerations

Evaluate for tuberculosis (TB) before initiating treatment

Next:

Interactions

Interaction Checker

and ixekizumab

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (12)

            • adenovirus types 4 and 7 live, oral

              ixekizumab decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • BCG vaccine live

              ixekizumab decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • influenza virus vaccine quadrivalent, intranasal

              ixekizumab decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • measles mumps and rubella vaccine, live

              ixekizumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • measles, mumps, rubella and varicella vaccine, live

              ixekizumab decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • rotavirus oral vaccine, live

              ixekizumab decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • smallpox (vaccinia) vaccine, live

              ixekizumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • typhoid polysaccharide vaccine

              ixekizumab decreases effects of typhoid polysaccharide vaccine by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • typhoid vaccine live

              ixekizumab decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • varicella virus vaccine live

              ixekizumab decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • yellow fever vaccine

              ixekizumab decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            • zoster vaccine live

              ixekizumab decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Ixekizumab may interfere with immune response of live vaccines and increase risk for vaccine adverse effects; prior to initiating ixekizumab, complete all age appropriate immunizations.

            Serious - Use Alternative (13)

            • anthrax vaccine adsorbed

              ixekizumab decreases effects of anthrax vaccine adsorbed by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • diphtheria & tetanus toxoids/ acellular pertussis vaccine

              ixekizumab decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine

              ixekizumab decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • influenza virus vaccine quadrivalent, recombinant

              ixekizumab decreases effects of influenza virus vaccine quadrivalent, recombinant by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • influenza virus vaccine trivalent, recombinant

              ixekizumab decreases effects of influenza virus vaccine trivalent, recombinant by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • meningococcal A C Y and W-135 diphtheria conjugate vaccine

              ixekizumab decreases effects of meningococcal A C Y and W-135 diphtheria conjugate vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • meningococcal A C Y and W-135 polysaccharide vaccine combined

              ixekizumab decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • meningococcal group B vaccine

              ixekizumab decreases effects of meningococcal group B vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • pneumococcal vaccine 13-valent

              ixekizumab decreases effects of pneumococcal vaccine 13-valent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • pneumococcal vaccine heptavalent

              ixekizumab decreases effects of pneumococcal vaccine heptavalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • pneumococcal vaccine polyvalent

              ixekizumab decreases effects of pneumococcal vaccine polyvalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine

              ixekizumab decreases effects of tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            • tetanus toxoid adsorbed or fluid

              ixekizumab decreases effects of tetanus toxoid adsorbed or fluid by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating ixekizumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with ixekizumab may not elicit an immune response sufficient to prevent disease.

            Monitor Closely (25)

            • carbamazepine

              ixekizumab, carbamazepine. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • clonidine

              ixekizumab, clonidine. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • cyclosporine

              ixekizumab, cyclosporine. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • dengue vaccine

              ixekizumab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.

            • disopyramide

              ixekizumab, disopyramide. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • ethosuximide

              ixekizumab, ethosuximide. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • fosphenytoin

              ixekizumab, fosphenytoin. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • haemophilus influenzae type b vaccine

              ixekizumab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. .

            • ifosfamide

              ifosfamide, ixekizumab. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.

            • lomustine

              lomustine and ixekizumab both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.

            • mechlorethamine

              mechlorethamine, ixekizumab. immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections. .

            • ofatumumab SC

              ofatumumab SC, ixekizumab. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC.

            • phenobarbital

              ixekizumab, phenobarbital. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • phenytoin

              ixekizumab, phenytoin. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • primidone

              ixekizumab, primidone. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • quinidine

              ixekizumab, quinidine. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • quinine

              ixekizumab, quinine. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • sirolimus

              ixekizumab, sirolimus. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • tacrolimus

              ixekizumab, tacrolimus. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • theophylline

              ixekizumab, theophylline. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • trastuzumab

              trastuzumab, ixekizumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .

            • trastuzumab deruxtecan

              trastuzumab deruxtecan, ixekizumab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .

            • valproic acid

              ixekizumab, valproic acid. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • warfarin

              ixekizumab, warfarin. Other (see comment). Use Caution/Monitor. Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.

            • zoster vaccine recombinant

              ixekizumab decreases effects of zoster vaccine recombinant by pharmacodynamic synergism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant.

            Minor (0)

              Previous
              Next:

              Adverse Effects

              >10%

              Injection site reactions (17%)

              Upper respiratory tract infections (14%)

              1-10%

              Thrombocytopenia, Grade 1 (3%)

              Nausea (2%)

              Tinea infections (2%)

              <1%

              Serious hypersensitivity reactions

              Serious infections

              Neutropenia

              Rhinitis

              Oral candidiasis

              Urticaria

              Influenza

              Conjunctivitis

              Inflammatory bowel disease

              Angioedema

              Postmarketing Reports

              Immune system disorders: Anaphylaxis

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity reaction (eg, anaphylaxis) to drug or excipients

              Cautions

              Serious hypersensitivity reactions reported, including angioedema and urticaria; anaphylaxis reported, some requiring hospitalization; if a serious hypersensitivity reaction occurs, discontinue drug immediately and initiate appropriate therapy

              Patients receiving treatment may be at increased risk of inflammatory bowel disease; in clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in treated group than placebo control group; during treatment, monitor for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue therapy and initiate appropriate medical management

              Risk of infections

              • May increase risk of infection; upper respiratory tract infections, oral candidiasis, conjunctivitis, and tinea infections reported
              • Instruct patients to seek medical advice if signs or symptoms of infection occur
              • If a serious infection develops or infection is not responding to standard therapy, monitor patient closely and discontinue therapy until infection resolves

              Tuberculosis evaluation

              • Evaluate patients for TB prior to initiating treatment
              • Do not administer to patients with active TB
              • Initiate treatment of latent TB prior to administering therapy
              • Consider anti-TB therapy prior to initiating in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed
              • Monitor closely for signs and symptoms of active TB during and after treatment

              Drug interaction overview

              • Prior to initiating drug, consider completion of all age-appropriate immunizations; avoid use of live vaccines; no data are available on the response to live vaccines while taking ixekizumab
              • Altering CYP450 enzymes
                • Formation of CYP450 enzymes can be altered by increased levels of certain cytokines (eg, IL-1, IL-6, IL-10, TNF-alpha, IFN) during chronic inflammation; thus, ixekizumab, an IL-17A antagonist, could normalize the formation of CYP450 enzymes
                • Upon initiating or discontinuing ixekizumab in patients receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (eg, warfarin) or drug concentration (eg, cyclosporine) and consider dosage modification of the CYP450 substrate
              Previous
              Next:

              Pregnancy

              Pregnancy

              There are no available data regarding use in pregnant women to inform any drug-associated risks

              Human IgG is known to cross the placental barrier; therefore, ixekizumab may be transmitted from the mother to the developing fetus

              Animal studies

              • Unknown if distributed in human breast milk
              • Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

              Lactation

              Unknown if distributed in human breast milk

              Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Humanized monoclonal IgG4 antibody that targets interleukin-17A (IL-17A) and neutralizes the proinflammatory effects of IL-17A

              IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses and plays a key role in the pathogenesis of plaque psoriasis

              Absorption

              Bioavailability: 60-81%; higher when administered in thigh vs arm or abdomen

              Peak plasma time: 4 days

              Peak plasma concentration: 16.2 mcg/mL

              Steady-state

              • 60 mg once, THEN 80 mg q2 Weeks dosing regimen: Reached at Week 8
              • Switching from 80 mg q2Weeks to 80 mg q4Weeks dosing regimen: Reached at Week 12

              Steady-state trough plasma concentration

              • 60 mg once, THEN 80 mg q2 Weeks dosing regimen: 9.3 mcg/mL
              • Switching from 80 mg q2Weeks to 80 mg q4Weeks dosing regimen: 3.5 mcg/mL

              Distribution

              Vd (steady-state): 7.11 L (increased with increased weight)

              Metabolism

              The metabolic pathway has not been characterized

              Humanized IgG4 monoclonal antibodies are expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG

              Elimination

              Half-life: 13 days

              Systemic clearance: 0.39 L/day (increased with increased weight)

              Previous
              Next:

              Administration

              SC Preparation

              Remove autoinjector or prefilled syringe from the refrigerator and allow to reach room temperature (30 min) without removing the needle cap

              Inspect visually for particulate matter and discoloration before administration; solution should appear as a clear and colorless to slightly yellow

              Do not use if the liquid contains visible particles or is discolored or cloudy (other than clear and colorless to slightly yellow)

              Does not contain preservatives; therefore, discard any unused product remaining in the autoinjector or prefilled syringe

              Pediatric patients weighing <50 kg

              • Use only the commercial ixekizumab 80 mg/1 mL prefilled syringe when preparing the prescribed 20 mg and 40 mg pediatric dose
              • Expel the entire contents of the prefilled syringe into a sterile vial; DO NOT shake or swirl the vial
              • Do not add any other medications to ixekizumab
              • Using 0.5 or 1 mL disposable syringe and sterile needle, withdraw dose from vial (0.25 mL for 20 mg; 0.5 mL for 40 mg)
              • Replace needle with a 27-gauge needle from syringe before administration

              SC Administration

              Intended for use under the guidance and supervision of a physician

              Patients may self-inject after training in SC injection technique using the autoinjector or prefilled syringe

              Instruct patients using the autoinjector or prefilled syringe to inject the full amount (1 mL), which provides 80 mg, according to the directions provided in the Instructions for Use provided in the Medication Guide supplied provided

              Administer each injection at a different anatomic location (eg, upper arms, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis

              Administration in the upper, outer arm may be performed by a caregiver or healthcare provider

              Missed dose: Administer as soon as possible; thereafter, resume dosing at the regular scheduled time

              Storage

              Sterile and preservative-free solution

              Protect from light until use

              Prepared syringe

              • Store at room temperature for up to 4 hr (from first puncturing vial)

              Prefilled syringe or autoinjector

              • Refrigerate at 2-8ºC (36-46ºF)
              • Do not freeze; do not use if drug has been frozen
              • Do not shake
              • Discard used syringe/autoinjector in a puncture-resistant container
              • Not made with natural rubber latex
              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.